Rutgers Cancer Institute of New Jersey (Site 103) — New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey (Site 103) is a clinical research site located in New Brunswick, New Jersey, United States 08901.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Rutgers Cancer Institute of New Jersey (Site 103) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC).

Sponsors: J-Pharma Co., Ltd..

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rutgers Cancer Institute of New Jersey (Site 103)?

Rutgers Cancer Institute of New Jersey (Site 103) has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rutgers Cancer Institute of New Jersey (Site 103) conducted?

Rutgers Cancer Institute of New Jersey (Site 103) has 1 clinical trials on record, with 1 currently active. Their work covers Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC).

Is Rutgers Cancer Institute of New Jersey (Site 103) accredited by Crixeo Health?

Rutgers Cancer Institute of New Jersey (Site 103) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rutgers Cancer Institute of New Jersey (Site 103)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.